Abivax (NASDAQ:ABVX) Now Covered by Truist Financial

Truist Financial began coverage on shares of Abivax (NASDAQ:ABVX) in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $140.00 target price on the stock.

ABVX has been the subject of a number of other research reports. Morgan Stanley lifted their price objective on shares of Abivax from $71.00 to $101.00 and gave the company an “overweight” rating in a report on Friday, September 12th. BTIG Research raised their target price on Abivax from $112.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Citigroup restated a “market outperform” rating on shares of Abivax in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, October 8th. Finally, JMP Securities raised their price objective on Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a report on Thursday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Abivax has an average rating of “Buy” and a consensus target price of $123.00.

Abivax Trading Up 5.5%

Shares of NASDAQ:ABVX opened at $125.71 on Monday. Abivax has a 12-month low of $4.77 and a 12-month high of $127.00. The business has a 50 day moving average of $95.43 and a two-hundred day moving average of $57.17. The company has a market capitalization of $9.78 billion, a PE ratio of -72.66 and a beta of 0.38.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, September 8th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. Equities research analysts predict that Abivax will post -2.83 earnings per share for the current fiscal year.

Institutional Trading of Abivax

Large investors have recently made changes to their positions in the company. Bank of America Corp DE raised its stake in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Abivax by 67.5% during the first quarter. Aberdeen Group plc now owns 710,516 shares of the company’s stock worth $4,441,000 after buying an additional 286,335 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of Abivax in the first quarter valued at about $1,250,000. Cubist Systematic Strategies LLC lifted its stake in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its position in Abivax by 3.3% during the first quarter. Nantahala Capital Management LLC now owns 1,482,994 shares of the company’s stock worth $9,269,000 after acquiring an additional 46,947 shares during the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.